- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 2, 2021
Regulation
Novavax preps for Q2 COVID vaccine EUA submission; plus Fibrogen, Inovio, J&J, Aslan, Merck, Oncopeptides and Athenex
Novavax Inc. (NASDAQ:NVAX) said in its 4Q20 earnings report that it is discussing COVID-19 vaccine NVX-CoV2373 with FDA and may submit a request for emergency use authorization of candidate next
BioCentury | Mar 7, 2020
Translation in Brief
Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery
BioCentury’s roundup of preclinical news
BioCentury | Dec 3, 2019
Financial News
Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron
BioCentury | Nov 8, 2019
Clinical News
AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb
BioCentury | Jun 2, 2019
Company News
Aslan’s change of course on eczema asset brings flexibility for future deals
BioCentury | Jun 22, 2018
Targets & Mechanisms
T cell balancing act
The latest debate in CAR T is whether CD8+ or CD4+ cells play the bigger role
BioCentury | Aug 4, 2016
Distillery Therapeutics
Therapeutics: Epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu); interleukin-13 receptor α 2 (IL-13RA2; IL-13R; CD213A2)
Items per page:
1 - 10 of 16